Invention Grant
- Patent Title: Pharmaceutical composition containing mTOR inhibitor for treating macular degeneration
-
Application No.: US16327850Application Date: 2017-03-17
-
Publication No.: US10583150B2Publication Date: 2020-03-10
- Inventor: Young-Ill Lee , Steven Hyun Seung Lee , Tae Kwann Park
- Applicant: CUROGENE LIFE SCIENCES CO., LTD. , SOONCHUNHYANG UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION
- Applicant Address: KR Chungcheongbuk-Do
- Assignee: CuroGene Life Sciences Co., Ltd.
- Current Assignee: CuroGene Life Sciences Co., Ltd.
- Current Assignee Address: KR Chungcheongbuk-Do
- Agency: Hultquist, PLLC
- Agent Steven J. Hultquist
- Priority: KR10-2016-0116310 20160909; KR10-2017-0033986 20170317
- International Application: PCT/KR2017/002943 WO 20170317
- International Announcement: WO2018/048046 WO 20180315
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C07H21/02 ; A61K31/7105 ; C12N15/113 ; C12N15/86 ; A61P27/02
Abstract:
The present invention relates to a pharmaceutical composition for treating macular degeneration, and more particularly to a pharmaceutical composition for treating macular degeneration, which comprises an inhibitor of mTOR gene expression. The pharmaceutical composition according to the present invention can effectively treat age-related macular degeneration, a representative retinal disease that causes blindness in adults.
Public/Granted literature
- US20190192551A1 PHARMACEUTICAL COMPOSITION CONTAINING mTOR INHIBITOR FOR TREATING MACULAR DEGENERATION Public/Granted day:2019-06-27
Information query
